Patient response rates to hepatitis C therapy can be variable, depending on factors such as viral genotype and subtype,
and liver fibrosis. Patients with genotype
1a, IL28B genotype TT
and METAVIR scores of F3
and F4 can be particularly challenging to cure," said Maria Beumont, M.D., medical leader for simeprevir, Janssen. "Janssen is committed to advancing hepatitis C therapy for even the most difficult-to-cure patients.